Why Mesa Laboratories, Inc.’s (MLAB) Stock Is Up 7.89%
As of Wednesday, August 19, Mesa Laboratories, Inc.’s MLAB share price has surged by 7.89%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Mesa Laboratories, Inc. (MLAB)
Mesa Laboratories, Inc. MLAB
$126.54
-0.60
-0.47%
September 18, 2026 4:00:00 PM
EST
Volume: 136,666
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment’s products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Commentary & Analysis
Is Mesa Laboratories, Inc. (MLAB) Overvalued?
We dive into why Mesa Laboratories, Inc. (MLAB) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
What You Need to Know About Mesa Laboratories, Inc.'s Q2 Earnings
Mesa Laboratories, Inc.'s fiscal Q2 earnings report was released on Monday, August 10. Let's dive in to see if (MLAB) missed or beat analyst's expectations.Jenna Brashear
Why Mesa Laboratories, Inc.’s (MLAB) Stock Is Up 5.04%
As of Thursday, July 09, Mesa Laboratories, Inc.’s MLAB share price has surged by 5.04%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Mesa Laboratories, Inc.’s (MLAB) Stock Is Down 5.61%
As of Monday, June 22, Mesa Laboratories, Inc.’s MLAB share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | MLAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $708.1 | $4,052.2 | 41% |
|
| Shares Out (Mil) | 5.8 | 98.2 | 15% |
|
| Institutional Ownership | 96.5% | 89.0% | 70% |
|
| Float (Mil) | 4.9 | 69.8 | 12% |
|
| Beta | 0.96 | 1.19 | 58% |
|
| Avg Daily Volume (000s) | 131 | 899 | 38% |
|
| Price Change (52-week) |
94.2% | 90.3% | 92% |
|
| Growth | MLAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 13.2% | 7.7% | 69% |
|
| Net Income (5yr) | 15.2% | (12.1%) | 64% |
|
| EPS (5yr) | 13.6% | 2.1% | 53 |
|
| Dividends (5yr) | 0.0% | 0.0% | 72% |
|
| Cash Flow (5yr) | (14.9%) | (14.9%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $2.240 | $9.950 | $10.270 | |
| Month Ago EPS | $2.240 | $9.950 | $10.270 | |
| # Rev Up | 1 | 0 | na | |
| # Rev Down | 0 | 1 | na | |
| Three Months Ago EPS | $2.730 | $11.620 | $12.270 | |
| Year/Year Chg | 357.1% | 722.3% | na | |
| Financials | MLAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $250 | $810 | 34% |
|
| Net Income (TTM) (Mil) | $5 | ($31) | 43% |
|
| EPS (TTM) | $0.863 | ($0.300) | 59% |
|
| Operating Cash Flow (TTM) (Mil) | $56 | $56 | 47% |
|
| Net Cash Flow (TTM) (Mil) | $9 | $3 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $153 | $252 | 47% |
|
| Enterprise Value (Q1) (Mil) | $841 | $3,264 | 39% |
|
| Valuation | MLAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.75 | 3.75 | 72% |
|
| P/E | 147.0 | 41.5 | 96% |
|
| Dividend Yield | 0.5% | 0.0% | 62% |
|
| PEG (5yr hist) | 10.8 | 5.9 | 94% |
|
| Ratios | MLAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.2% | 47.6% | 76% |
|
| Net Margin | 1.9% | (4.6%) | 37% |
|
| ROA | 1.1% | (4.7%) | 47% |
|
| ROE | 2.7% | (7.7%) | 39% |
|
| Liabilities to Assets | 55.0% | 41.1% | 48% |
|
| F-Score | 7 | 5 | 82% |
|
Mesa Laboratories, Inc. did not pass any screens on 9/18/2026.
